<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00794417</url>
  </required_header>
  <id_info>
    <org_study_id>VGFT-ST-0708</org_study_id>
    <secondary_id>TCD10767</secondary_id>
    <nct_id>NCT00794417</nct_id>
  </id_info>
  <brief_title>A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma</brief_title>
  <official_title>A Phase 1/2 Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether the combination of aflibercept, pemetrexed
      and cisplatin is safe and effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in two phases. In phase 1, patients with advanced cancer will
      receive different doses of aflibercept in combination with approved doses of pemetrexed and
      cisplatin. The objective of phase 1 is to determine the safest dose of the combined study
      medications. This dose will then be administered to patients with previously untreated
      non-small cell lung cancer in phase 2. The phase 2 portion of the study will determine if the
      combination is effective in treating non-small cell lung cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Dose limiting toxicities; Phase 2: Objective Response Rate (ORR) and Progression Free Survival (PFS)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, pharmacokinetic and immunogenic profile of aflibercept when given in combination with pemetrexed and cisplatin</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Advanced Carcinoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Administered in combination with the other two interventions via intravenous infusion.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Administered in combination with the other two interventions via intravenous infusion.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered in combination with the other two interventions via intravenous infusion.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmation of cancer by biopsy (tissue sample)

          -  Phase 1: patients with advanced or metastatic disease that have failed conventional
             therapy

          -  Phase 2: patients with previously untreated NSCLC, excluding squamous cell histology
             and cavitating lesions

          -  Age â‰¥18 years

          -  ECOG performance status 0-1

          -  Adequate renal, liver and bone marrow function.

          -  Negative pregnancy test (serum or urine) in females of childbearing potential within 7
             days of the initial dose of aflibercept

          -  Ability to comply with scheduled visits, treatment plans, laboratory tests, and other
             study procedures

          -  Institutional Review Board (IRB) approved, signed and dated informed consent form

        Exclusion Criteria:

          -  Prior treatment with study medications

          -  Untreated, symptomatic, or progressive Central Nervous System cancer and/or spinal
             cord compression. Patients with treated brain metastases must have been without
             symptoms for at least 3 months

          -  Surgery up to 4 weeks prior to the initial administration of aflibercept and/or
             incomplete wound healing

          -  Anti-VEGF therapy up to 4 weeks prior to the initial administration of aflibercept
             (for phase 1 only)

          -  Chemotherapy up to 4 weeks prior to the initial administration of aflibercept (for
             phase 1 only)

          -  Other investigational treatment up to 4 weeks prior to the initial administration of
             aflibercept

          -  Any of the following up to 6 months (24 weeks) prior to the initial administration of
             aflibercept:

               -  Severe cardiovascular disease or event

               -  Cerebrovascular accident, transient ischemic attack, or moderate to severe
                  peripheral neuropathy

               -  Erosive esophagitis or gastritis, infectious or inflammatory bowel disease, and
                  diverticulitis

               -  Deep vein thrombosis, pulmonary embolism, or other clotting event

               -  Episode(s)of moderate to severe, continuous bleeding

          -  Breast-feeding or pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Institute, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Science</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Institute of Hematology and Oncology</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hines Jr. VA Medical Center</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Cancer Clinic</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNM Cancer Clinic</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital Center for Cancer Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erie Regional Cancer Center</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiffler Cancer Center - Medical Oncology Division</name>
      <address>
        <city>Wheeling</city>
        <state>West Virginia</state>
        <zip>26003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2008</study_first_submitted>
  <study_first_submitted_qc>November 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2008</study_first_posted>
  <disposition_first_submitted>April 17, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>April 17, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 27, 2011</disposition_first_posted>
  <last_update_submitted>August 30, 2012</last_update_submitted>
  <last_update_submitted_qc>August 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced cancer</keyword>
  <keyword>lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>aflibercept</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

